Seroquel

See also: Generic Seroquel XR

Seroquel is a brand name of quetiapine, approved by the FDA in the following formulation(s):

SEROQUEL (quetiapine fumarate - tablet; oral)

• 
  Manufacturer: ASTRAZENECA
  
  Approval date: September 26, 1997
  
  Strength(s): EQ 100MG BASE, EQ 200MG BASE, EQ 25MG BASE ^[RLD]


• 
  Manufacturer: ASTRAZENECA
  
  Approval date: July 26, 2000
  
  Strength(s): EQ 300MG BASE ^[RLD]


• 
  Manufacturer: ASTRAZENECA
  
  Approval date: October 4, 2005
  
  Strength(s): EQ 400MG BASE, EQ 50MG BASE
  

Has a generic version of Seroquel been approved?

No. There is currently no therapeutically equivalent version of Seroquel available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Seroquel. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Novel dibenzothiazepine antipsychotic
  Patent 4,879,288
  Issued: November 7, 1989
  Inventor(s): Warawa; Edward J. & Migler; Bernard M.
  Assignee(s): ICI Americas Inc.
  11-[4-[2-(2-Hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo[b,f][1,4 ]thiazepine is disclosed as a neuroleptic with a much reduced incidence of side effects such as acute dystonia and dyskinesia and tardive diskinesia.
  
  Patent expiration dates:
  
  
  • September 26, 2011
    
    ✓ 
    Patent use: TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • March 26, 2012
    
    ✓ 
    Pediatric exclusivity
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • May 13, 2011 - MAINTENANCE TREATMENT FOR BIPOLAR I DISORDER, AS ADJUNCTIVE THERAPY TO LITHIUM OR DIVALPROEX
  
  
  • November 13, 2011 - PEDIATRIC EXCLUSIVITY
  
  
  • December 2, 2012 - NEW PATIENT POPULATION
  
  
  • June 2, 2013 - PEDIATRIC EXCLUSIVITY
  
  

See also...

• Seroquel Consumer Information (Drugs.com)
• Seroquel Consumer Information (Wolters Kluwer)
• Seroquel Consumer Information (Cerner Multum)
• Seroquel Advanced Consumer Information (Micromedex)
• Seroquel AHFS DI Monographs (ASHP)
• Quetiapine Consumer Information (Wolters Kluwer)
• Quetiapine Sustained-Release Tablets Consumer Information (Wolters Kluwer)
• Quetiapine Consumer Information (Cerner Multum)
• Quetiapine Advanced Consumer Information (Micromedex)
• Quetiapine Fumarate AHFS DI Monographs (ASHP)